Cover Image
Read Now

Prostate-specific antigen-based screening for prostate cancer a systematic evidence review for the U.S. Preventive Services Task Force /

Biopsy-related harms include moderate to severe pain (7.3% at 35 days [95% CI, 5.7% to 9.1%]), infectious complications (range, 2% to 7%), and hospitalization (approximately 1%). Excess incidence data from the PLCO and ERSPC trials imply that between 20.7 percent and 50.4 percent of screen-detected...

Full description

Bibliographic Details
Main Author: Fenton, Joshua J.
Corporate Authors: University of California, Davis Center for Healthcare Policy and Research, Oregon Evidence-based Practice Center (Center for Health Research (Kaiser-Permanente Medical Care Program. Northwest Region)), United States Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force
Format: eBook
Language:English
Published: Rockville, MD Agency for Healthcare Research and Quality 2018, May 2018
Series:Evidence synthesis
Subjects:
Prostate-specific Antigen
Prostatic Neoplasms / Diagnosis
Mass Screening
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Table of Contents:
  • Includes bibliographical references

Similar Items